Citations

Showing 10 of 108083 citations.

Cannabis in Cancer Survivors Who Report High Impact Chronic Pain: Findings from a 1500+ Patient Survey
Ramar, Priya , Jatoi, Aminah , Rosedahl, Jordan K., Canning, Rachel, Ebbert, Jon O. , Jatoi, Aminah , Rosedahl, Jordan, Ebbert, Jon O , Philpot, Lindsey M.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | December 5, 2022 | Volume: 40 | Issue: 11 | Pages: 1196-1204

10.1177/10499091221143098 | PMID 36469631 Get It

Background Chronic pain in cancer survivors negatively impacts quality of life. This study sought to investigate the relationship between high-impact chronic pain (HICP) -- defined as chronic pain that limits life or work activities on most days or every day in the past 3 months -- and cannabis in cancer survivors. Methods An electronic survey was developed in conjunction with the National Cancer Institute Comprehensive Cancer Centers in the United States. This survey was distributed to cancer survivors within a multi-site, single institution setting. Results The survey response rate was 23.0% (2304/10,000); 72.7% of these patients (1676/2304) did in fact have a confirmed cancer diagnosis. Among these cancer survivors, 16.5% (unweighted 278/1676) had HICP, and 12.4% (208/1676) reported cannabis use since their cancer diagnosis. The prevalence of past 30-day cannabis use was 12.3% (206/1676). Compared to cancer survivors without pain, those with HICP were more likely to believe in the benefits of cannabis (unweighted 92.1% vs. 74.7%; age-adjusted odds ratio [OR] = 3.1; 95% CI: 1.9-5.1) and less likely to believe in its risks (unweighted 48.2% vs. 58.4%; age-adjusted OR = 0.6; 95% CI: 0.4-0.7). Conclusions Cancer survivors with HICP have a higher prevalence of cannabis use compared to those patients without pain. More research is needed to advance pain and symptom management among cancer survivors and to identify clinical scenarios in which benefit is greater than potential harm.
Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
Wei, Lixuan , Gao, Huanyao , Yu, Jia , Zhang, Huan , Nguyen, Thanh Thanh L. , Gu, Yayun , Passow, Marie R. , Carter, Jodi M. , Qin, Bo , Boughey, Judy C. , Weinshilboum, Richard M. , Wang, Liewei , Boughey, JC , Goetz, Matthew P , Weinshilboum, Richard M. , Ingle, J , Wang, Liewei , Nguyen, Thanh Thanh L. , Carter, Jodi , Goetz, Matthew P. , Ingle, James N.

Mayo Clinic

Cancer Research | December 5, 2022 | Volume: 83 | Issue: 3 | Pages: 456-470

10.1158/0008-5472.can-22-1016 | PMID 36469363 Get It

Abstract Androgen receptor (AR) is expressed in 80% to 90% of estrogen receptor α–positive (ER+) breast cancers. Accumulated evidence has shown that AR is a tumor suppressor and that its expression is associated with improved prognosis in ER+ breast cancer. However, both a selective AR agonist (RAD140) and an AR inhibitor (enzalutamide, ENZ) have shown a therapeutic effect on ER+ breast cancer, so the potential for clinical application of AR-targeting therapy for ER+ breast cancer is still in dispute. In this study, we evaluated the efficacy of ENZ and RAD140 in vivo and in vitro in AR+/ER+ breast cancer models, characterizing the relationship of AR and ER levels to response to AR-targeting drugs and investigating the alterations of global gene expression and chromatin binding of AR and ERα after ENZ treatment. In the AR-low setting, ENZ directly functioned as an ERα antagonist. Cell growth inhibition by ENZ in breast cancer with low AR expression was independent of AR and instead dependent on ER. In AR-high breast cancer models, AR repressed ERα signaling and ENZ promoted ERα signaling by antagonizing AR. In contrast, RAD140 activated AR signaling and suppressed AR-high tumor growth by deregulating ERα expression and blocking ERα function. Overall, analysis of the dynamic efficacies and outcomes of AR agonist, and antagonist in the presence of different AR and ERα levels reveals regulators of response and supports the clinical investigation of ENZ in selected ER+ tumors with a low AR/ER ratio and AR agonists in tumors with a high AR/ER ratio. Significance: The ratio of androgen receptor to estrogen receptor in breast cancer dictates the response to AR-targeted therapies, providing guidelines for developing AR-directed treatment strategies for patients with breast cancer.
Reduce, Reuse, Recycle: Top 10 Choosing Wisely Canada’s Recommendations for Conserving Laboratory Resources
Beriault, Daniel R. , Rodríguez-Capote, Karina , Kinniburgh, David W. , Langman, Loralie J., Mattman, André , Konforte, Danijela , Olechuk, Curtis, Beach, Lori , Leung, Felix , Arnoldo, Saranya , Knauer, Michael , Kalra, Jay , Bouhtiauy, Ihssan, Hassan, Mohamed Abou El, Bailey, Dana , Catomeris, Peter, Simons, Janet , Knauer, Michael J. , Beriault, Daniel R , Knauer, Michael , Hauff, Kristin D. , Chen, Yu , Elnenaei, Manal O.

Mayo Clinic

Canadian Journal of General Internal Medicine | December 5, 2022 | Volume: 17 | Issue: 4 | Pages: 86-95

10.22374/cjgim.v17i4.650 Get It

The COVID-19 pandemic has significantly impacted the production, distribution, and demand of essential laboratory supplies worldwide. In 2021, severe shortages in required laboratory supplies such as blood collection tubes, butterfly needles, and blood gas syringes became a critical issue across Canada. Many hospitals or institutions had to instruct physicians and patients to limit laboratory testing where possible and, in some cases, required emergency shipments of tubes from alternative vendors or nearby hospitals. Laboratory testing is ubiquitous in managing patients. It is used for screening, diagnosis, and monitoring purposes. With limited blood collection tubes, consideration for restricting non-urgent testing is needed to conserve supply and protect acute care departments that manage critically ill patients. In addition, laboratories across Canada have experienced significant staffing shortages, resulting in an even greater need for appropriate laboratory utilization. Consequently, the Canadian Society of Clinical Chemists (CSCC) and the Canadian Association of Medical Biochemists (CAMB) curated utilization recommendations for both hospital and primary care settings in collaboration with Choosing Wisely Canada (CWC). These recommendations were specifically selected from those previously published by Choosing Wisely Canada (CWC), with impact statements and rationales added to conserve at-risk laboratory resources. Supply chain disruptions of clinical laboratory resources are expected to continue throughout 2022, indicating that now, more than ever, a focus on appropriate laboratory utilization is essential.
Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC
Kubi, Boateng , Nudotor, Richard , Fackche, Nadege , Rowe, Julian , Cloyd, Jordan M. , Grotz, Travis E. , Dineen, Seán , Veerapong, Jula , Baumgartner, Joel , Dhar, Vikrom K. , Lambert, Laura , Abbott, Daniel E. , Pokrzywa, Courtney , Raoof, Mustafa , Lee, Byrne , Zaidi, Mohammad Y. , Grotz, Travis E , Dineen, Sean P , Clarke, Callisia N , Patel, Sameer H , Dhar, Vikrom , Abbott, Daniel E , Raoof, Mustafa , Zaidi, Mohammad Y , Maithel, Shishir K , Johnston, Fabian M , Ahmed, Ahmed , Fournier, Keith F. , Clarke, Callisia N. , Greer, Jonathan B.

Mayo Clinic

Journal of Surgical Oncology | December 5, 2022 | Volume: 127 | Issue: 4 | Pages: 706-715

10.1002/jso.27147 | PMID 36468401 Get It

AbstractBackgroundCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is increasingly performed for peritoneal surface malignancies but remains associated with significant morbidity. Scant research is available regarding the impact of insurance status on postoperative outcomes.MethodsPatients undergoing CRS/HIPEC between 2000 and 2017 at 12 participating sites in the US HIPEC Collaborative were identified. Univariate and multivariate analyses were used to compare the baseline characteristics, operative variables, and postoperative outcomes of patients with government, private, or no insurance.ResultsAmong 2268 patients, 699 (30.8%) had government insurance, 1453 (64.0%) had private, and 116 (5.1%) were uninsured. Patients with government insurance were older, more likely to be non‐white, and comorbid (p < 0.05). Patients with government (OR: 2.25, CI: 1.50−3.36, p < 0.001) and private (OR: 1.69, CI: 1.15−2.49, p = 0.008) insurance had an increased risk of complications on univariate analysis. There was no independent relationship on multivariate analysis. An American Society of Anesthesiologists score of 3 or 4, peritoneal carcinomatosis index score >15, completeness of cytoreduction score >1, and nonhome discharge were factors independently associated with a postoperative complication.ConclusionWhile there were differences in postoperative outcomes between the three insurance groups on univariate analysis, there was no independent association between insurance status and postoperative complications after CRS/HIPEC.
Aesthetic considerations when treating the Latin American patient: Thriving in diversity international roundtable series
Fabi, Sabrina G. , Hernandez, Claudia A, Montes, José Raúl , Cotofana, Sebastian , Dayan, Steve, Cotofana, Sebastian

Mayo Clinic

Journal of Cosmetic Dermatology | December 5, 2022 | Volume: 22 | Issue: 2 | Pages: 593-602

10.1111/jocd.15516 | PMID 36468194 Get It

AbstractBackgroundThe Hispanic/Latin American population is the fastest growing non‐Caucasian group in the United States. Within this group, demand for aesthetic procedures is on the rise. High ethnic variability among these patients influences treatment approaches and patient priorities. Understanding these ethnic differences is central to providing optimal care.AimsTo discuss similarities and differences in anatomy and treatment preferences of Hispanic/Latin American patients both within the United States and internationally and explore how these differences may influence or inform aesthetic practices.Patients/MethodsIn support of clinicians who wish to serve a diverse patient population, a 6‐part, international roundtable series focused on diversity in aesthetics was conducted from August 24, 2021 to May 16, 2022. In this roundtable, held in Medellin, Columbia, expert clinicians from across Latin America and the United States were invited to contribute and share best practices.ResultsThe results of the second roundtable in the series, the Latin American Patient, are described here. A special emphasis is placed on procedures that address the most commonly encountered concerns in these patients.ConclusionsHispanic and Latino patients represent a broad demographic with unique anatomical features, aesthetic preferences, and treatment priorities. Clinicians should consider these differences when treating this patient population.
Mid- and Late-Life Physical Activity and Neuropsychiatric Symptoms in Dementia-Free Older Adults: Mayo Clinic Study of Aging
Krell‐Roesch, Janina , Syrjanen, Jeremy A. , Bezold, Jelena, Trautwein, Sandra , Barisch‐Fritz, Bettina , Kremers, Walter K. , Fields, Julie A. , Petersen, Ronald C. , Jekauc, Darko , Vassilaki, Maria , Geda, Yonas E. , Stokin, Gorazd B. , Wöll, Alexander , Geda, Yonas E , Kremers, Walter K , Scharf, Eugene , Knopman, David S.

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | December 5, 2022 | Volume: 35 | Issue: 2 | Pages: 133-140

10.1176/appi.neuropsych.20220068 | PMID 36464975 Get It

Predictors of Total Hip Arthroplasty Following Pediatric Surgical Treatment of Developmental Hip Dysplasia at 20-Year Follow-Up
Young, Ernest, Regan, Christina , Milbrandt, Todd A. , Grigoriou, Emmanouil , Shaughnessy, William J. , Stans, Anthony A. , Larson, A. Noelle

Mayo Clinic

Journal of Clinical Medicine | December 5, 2022 | Volume: 11 | Issue: 23 | Pages: 7198

10.3390/jcm11237198 | PMID 36498771 Get It

Long-term outcomes of surgical treatment for pediatric developmental dysplasia of the hip (DDH) are not well defined. The purpose of this study was to report long-term radiographic and clinical outcomes, survivorship free of total hip arthroplasty (THA), and predictors of subsequent THA following childhood treatment of DDH. This study was a single-institution retrospective review of hips treated for DDH with closed or open reduction at a minimum 10-year follow-up. 107 patients (119 hips) were included with a mean patient age of 3.3 years at childhood treatment. At mean 30.5 years follow-up, 24 hips had undergone THA (20%). Mean patient age at time of THA was 33.5 years. None of the hips treated with closed reduction alone required THA, whereas 8 hips treated with open reduction (25%) underwent THA. Hips with patient age > 4 years at the time of treatment had lower survivorship at 35 years follow-up (50% vs. 85%; p < 0.001). Additionally, femoral osteotomy (OR 2.0, p < 0.001), and previous treatment elsewhere (27% vs. 16%; p < 0.01) were associated with subsequent THA. Early referral and appropriate intervention may prove important, as age and prior treatment were predictive of subsequent THA.
The Role of Primary Cilia-Associated Phosphoinositide Signaling in Development
Chen, Chuan , Hu, Jinghua , Ling, Kun , Chen, Chuan

Mayo Clinic

Journal of Developmental Biology | December 5, 2022 | Volume: 10 | Issue: 4 | Pages: 51

10.3390/jdb10040051 | PMID 36547473 Get It

Primary cilia are microtube-based organelles that extend from the cell surface and function as biochemical and mechanical extracellular signal sensors. Primary cilia coordinate a series of signaling pathways during development. Cilia dysfunction leads to a pleiotropic group of developmental disorders, termed ciliopathy. Phosphoinositides (PIs), a group of signaling phospholipids, play a crucial role in development and tissue homeostasis by regulating membrane trafficking, cytoskeleton reorganization, and organelle identity. Accumulating evidence implicates the involvement of PI species in ciliary defects and ciliopathies. The abundance and localization of PIs in the cell are tightly regulated by the opposing actions of kinases and phosphatases, some of which are recently discovered in the context of primary cilia. Here, we review several cilium-associated PI kinases and phosphatases, including their localization along cilia, function in regulating the ciliary biology under normal conditions, as well as the connection of their disease-associated mutations with ciliopathies.
Management of long‐term home parenteral nutrition: Historical perspective, common complications, and patient education and training
Mundi, Manpreet S. , Bonnes, Sara L. , Salonen, Bradley R. , Mohamed Elfadil, Osman , Hurt, Ryan T. , Bonnes, Sara, Mundi, Manpreet S , Elfadil, Osman Mohamed

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | December 5, 2022 | Volume: 47 | Issue: S1 | Pages: No page available

10.1002/jpen.2424 | PMID 36468330 Get It

Abstract Intestinal failure (IF) is a rare disease that requires ongoing intravenous supplementation to sustain growth and health. Advancements in parenteral nutrition (PN) and central venous access in the 1960s and 1970s transformed a life‐limiting disease to a chronic one in which patients are able to administer hydration, electrolytes, micronutrients, and macronutrients in the comfort of their home. However, despite ongoing advancements in the field of home PN (HPN), complications—whether related to central venous catheters or PN itself—remain common and can be associated with significant morbidity and mortality. Central venous access can be associated with thrombosis, central line–associated bloodstream infection, or damage and can result in loss of access over time. PN can be associated with IF‐associated liver disease or hyperglycemia. The key to preserving central venous access and quality of life and maintaining health for patients with chronic IF (CIF) is education focused on prevention and prompt management of CIF complications as they arise. This education typically takes place at the time of initiation of HPN, either in the hospital setting or in the patient's home. The present manuscript describes the historical progression of HPN, prevalence and characteristics of CIF, and an in‐depth discussion of the most common catheter‐related and PN‐related complications and their management, along with a discussion of our education and training process.
Tranexamic acid for patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of 2991 patients
Ghaith, Hazem S. , Gabra, Mohamed Diaa , Ebada, Mahmoud Ahmed , Dada, Olaoluwa Ezekiel , Al-Shami, Hieder , Bahbah, Eshak I. , Kanmounye, Ulrick Sidney , Negida, Ahmed , Swed, Sarya , Kanmounye, Ulrick Sidney , Negida, Ahmed , Ghaith, Abdul Karim , Esene, Ignatius Ngene

Mayo Clinic

International Journal of Neuroscience | December 4, 2022 | Volume: 134 | Issue: 7 | Pages: 763-776

10.1080/00207454.2022.2148957 | PMID 36463556 Get It